Literature DB >> 16215712

Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis.

S Harbarth1, J Garbino, J Pugin, J A Romand, D Pittet.   

Abstract

In order to determine whether combination antibiotic therapy decreases mortality after severe pneumococcal infection, a retrospective study of a cohort of 1,840 adult patients with severe sepsis or septic shock enrolled in two multicenter clinical trials between 1994 and 1999 was conducted. Among 107 patients with monobacterial pneumococcal sepsis, the case-fatality rate was 20% (five of 25) for patients who received antibiotic monotherapy compared with 19.5% (16 of 82) for patients who received combination therapy (adjusted hazard ratio, 1.1; 95% CI, 0.4-3.1). Similarly, monotherapy did not increase the risk of death (adjusted hazard ratio, 1.0; 95% CI, 0.2-4.8) among bacteremic patients (n=75). However, the latter analysis may have been underpowered (power, 58%) to detect a difference in mortality. Overall, in contrast to recently published reports, these results suggest that combination antibiotic therapy does not decrease mortality after severe pneumococcal sepsis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16215712     DOI: 10.1007/s10096-005-0018-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia?

Authors:  Thomas M File; Lionel A Mandell
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

2.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

Authors:  José A Martínez; Juan P Horcajada; Manuel Almela; Francesc Marco; Alex Soriano; Elisa García; Maria Angeles Marco; Antoni Torres; Josep Mensa
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

3.  Microbiologic findings and correlations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock.

Authors:  J Cohen; E Abraham
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

4.  Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.

Authors:  E Abraham; P F Laterre; J Garbino; S Pingleton; T Butler; T Dugernier; B Margolis; K Kudsk; W Zimmerli; P Anderson; M Reynaert; D Lew; W Lesslauer; S Passe; P Cooper; A Burdeska; M Modi; A Leighton; M Salgo; P Van der Auwera
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

5.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.

Authors:  G W Waterer; G W Somes; R G Wunderink
Journal:  Arch Intern Med       Date:  2001 Aug 13-27

6.  p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

Authors:  E Abraham; M P Glauser; T Butler; J Garbino; D Gelmont; P F Laterre; K Kudsk; H A Bruining; C Otto; E Tobin; C Zwingelstein; W Lesslauer; A Leighton
Journal:  JAMA       Date:  1997-05-21       Impact factor: 56.272

7.  Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.

Authors:  Stephan Harbarth; Jorge Garbino; Jérome Pugin; Jacques A Romand; Daniel Lew; Didier Pittet
Journal:  Am J Med       Date:  2003-11       Impact factor: 4.965

Review 8.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.

Authors:  Larry M Baddour; Victor L Yu; Keith P Klugman; Charles Feldman; Ake Ortqvist; Jordi Rello; Arthur J Morris; Carlos M Luna; David R Snydman; Wen Chien Ko; M Bernadete F Chedid; David S Hui; Antoine Andremont; Christine C C Chiou
Journal:  Am J Respir Crit Care Med       Date:  2004-06-07       Impact factor: 21.405

  9 in total
  14 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy.

Authors:  Simone Gattarello
Journal:  Curr Infect Dis Rep       Date:  2015-10       Impact factor: 3.725

3.  Optimal antibiotic treatment in severe pneumococcal pneumonia--time for real answers.

Authors:  G W Waterer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

Review 4.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

5.  Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia.

Authors:  R Dwyer; A Ortqvist; E Aufwerber; B Henriques Normark; T J Marrie; M A Mufson; A Torres; M A Woodhead; M Alenius; M Kalin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

6.  Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.

Authors:  Thomas P Lodise; Andrea Kwa; Leon Cosler; Reetu Gupta; Raymond P Smith
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

7.  Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia.

Authors:  S Padrones; C Garcia-Vidal; S Fernández-Serrano; A Fernández; C Masuet; J Carratalà; M Coromines; C Ardanuy; F Gudiol; F Manresa; J Dorca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-22       Impact factor: 3.267

Review 8.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia.

Authors:  R Chokshi; M I Restrepo; N Weeratunge; C R Frei; A Anzueto; E M Mortensen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 3.267

10.  Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.

Authors:  Nicolas Mongardon; Adeline Max; Adrien Bouglé; Frédéric Pène; Virginie Lemiale; Julien Charpentier; Alain Cariou; Jean-Daniel Chiche; Jean-Pierre Bedos; Jean-Paul Mira
Journal:  Crit Care       Date:  2012-08-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.